Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 4.93M | 4.93M | -59.83M | -58.39M | -3.32 |
| 2023 FY | 33.49M | 33.49M | -30.67M | -27.70M | -1.19 |
| 2024 FY | 251.00K | 251.00K | -67.28M | -58.49M | -5.20 |
| 2025 FY | — | -2.60M | -90.61M | -83.87M | -3.43 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 133.05M | 273.75M | 102.53M | 19.45M | -140.70M |
| 2023 FY | 105.11M | 267.13M | 53.50M | 16.91M | -162.02M |
| 2024 FY | 209.58M | 22.94M | 40.24M | 14.35M | 186.64M |
| 2025 FY | 130.94M | 20.97M | 26.70M | 10.94M | 109.97M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -50.83M | -6.30M | -57.13M | — | -58.39M |
| 2023 FY | -47.43M | -3.26M | -50.69M | — | -49.01M |
| 2024 FY | -55.03M | -642.00K | -55.67M | — | -13.27M |
| 2025 FY | -76.75M | -2.59M | -79.34M | — | -13.33M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 211.00M | 127.92M | — | — | — |
| 2023 FY | 279.38M | 242.79M | — | — | — |
| 2024 FY | 245.58M | 219.70M | — | — | — |
| 2025 FY | 104.87M | 89.11M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | -22.81M | -21.25M | -0.87 |
| 2025 Q3 | — | — | -22.90M | -21.53M | -0.88 |
| 2025 Q4 | — | — | -21.93M | -20.77M | -0.85 |
| 2026 Q1 | — | -666.00K | -24.43M | -23.52M | -0.95 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 169.39M | 20.35M | 28.47M | 13.22M | 149.04M |
| 2025 Q3 | 148.86M | 19.64M | 25.51M | 11.69M | 129.22M |
| 2025 Q4 | 130.94M | 20.97M | 26.70M | 10.94M | 109.97M |
| 2026 Q1 | 105.96M | 18.11M | 20.96M | 10.26M | 87.85M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -22.98M | -1.06M | -24.04M | — | -1.93M |
| 2025 Q3 | -19.20M | -600.00K | -19.80M | — | -2.96M |
| 2025 Q4 | -14.73M | -421.00K | -15.15M | — | 1.19M |
| 2026 Q1 | -20.95M | -242.00K | -21.19M | — | -5.75M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 36.81M | 21.57M | — | — | — |
| 2025 Q3 | 70.26M | 56.45M | — | — | — |
| 2025 Q4 | 104.87M | 89.11M | — | — | — |
| 2026 Q1 | 158.93M | 148.24M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |